Hydralazine As a Selective Probe Inactivator of Aldehyde Oxidase in Human Hepatocytes: Estimation of the Contribution of Aldehyde Oxidase to Metabolic Clearance

Aldehyde oxidase (AO) metabolism could lead to significant underestimation of clearance in prediction of human pharmacokinetics as well as unanticipated exposure to AO-generated metabolites, if not accounted for early in drug research. We report a method using cryopreserved human hepatocytes and the time-dependent AO inhibitor hydralazine (KI = 83 ± 27 μM, kinact = 0.063 ± 0.007 min−1), which estimates the contribution of AO metabolism relative to total hepatic clearance. Using zaleplon as a probe substrate and simultaneously monitoring the AO-catalyzed formation of oxozaleplon and the CYP3A-catalyzed formation of desethyzaleplon in the presence of a range of hydralazine concentrations, it was determined that >90% inhibition of the AO activity with minimal effect on the CYP3A activity could be achieved with 25 to 50 μM hydralazine. This method was used to estimate the fraction metabolized due to AO [fm(AO)] for six compounds with clearance attributed to AO along with four other drugs not metabolized by AO. The fm(AO) values for the AO substrates ranged between 0.49 and 0.83. Differences in estimated fm(AO) between two batches of pooled human hepatocytes suggest that sensitivity to hydralazine varies slightly with hepatocyte preparations. Substrates with a CYP2D6 contribution to clearance were affected by hydralazine to a minor extent, because of weak inhibition of this enzyme. Overall, these findings demonstrate that hydralazine, at a concentration of 25 to 50 μM, can be used in human hepatocyte incubations to estimate the contribution of AO to the hepatic clearance of drugs and other compounds.

[1]  T. Naruke,et al.  Aldehyde oxidase-dependent marked species difference in hepatic metabolism of the sedative-hypnotic, zaleplon, between monkeys and rats. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[2]  Hiroshi Yamazaki,et al.  Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution. , 2010, Current drug metabolism.

[3]  Enrico Garattini,et al.  The role of aldehyde oxidase in drug metabolism , 2012, Expert opinion on drug metabolism & toxicology.

[4]  D. Rance,et al.  Oxidative metabolism of carbazeran in vitro by liver cytosol of baboon and man. , 1985, Xenobiotica; the fate of foreign compounds in biological systems.

[5]  M. Romão,et al.  Mammalian molybdo-flavoenzymes, an expanding family of proteins: structure, genetics, regulation, function and pathophysiology. , 2003, The Biochemical journal.

[6]  T. Baillie,et al.  Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. , 2002, Chemical research in toxicology.

[7]  Kuresh Youdim,et al.  In Vitro-In Vivo Correlation for Intrinsic Clearance for Drugs Metabolized by Human Aldehyde Oxidase , 2010, Drug Metabolism and Disposition.

[8]  Bryan M. Li,et al.  Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections. , 2009, Journal of medicinal chemistry.

[9]  J. Stell,et al.  Hydralazine: a potent inhibitor of aldehyde oxidase activity in vitro and in vivo. , 1985, Biochemical pharmacology.

[10]  R. Obach,et al.  Potent inhibition of human liver aldehyde oxidase by raloxifene. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[11]  G. S. Walker,et al.  Validation of Isolated Metabolites from Drug Metabolism Studies as Analytical Standards by Quantitative NMR , 2011, Drug Metabolism and Disposition.

[12]  Aleksandra Galetin,et al.  Prediction of Drug Clearance by Glucuronidation from in Vitro Data: Use of Combined Cytochrome P450 and UDP-Glucuronosyltransferase Cofactors in Alamethicin-Activated Human Liver Microsomes , 2009, Drug Metabolism and Disposition.

[13]  R. Obach,et al.  Cross-Species Comparison of the Metabolism and Excretion of Zoniporide: Contribution of Aldehyde Oxidase to Interspecies Differences , 2010, Drug Metabolism and Disposition.

[14]  S. Wrighton,et al.  Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. , 1994, Biochemical pharmacology.

[15]  Caroline A. Lee,et al.  Development of an in vitro drug-drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compounds. , 2008, Journal of pharmacological and toxicological methods.

[16]  E. Garattini,et al.  Increasing recognition of the importance of aldehyde oxidase in drug development and discovery , 2011, Drug metabolism reviews.

[17]  Robert J Riley,et al.  EVALUATION OF FRESH AND CRYOPRESERVED HEPATOCYTES AS IN VITRO DRUG METABOLISM TOOLS FOR THE PREDICTION OF METABOLIC CLEARANCE , 2004, Drug Metabolism and Disposition.

[18]  S. Clarke,et al.  Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[19]  J. Wanders,et al.  Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. , 2002, European journal of cancer.

[20]  T. Maduskuie,et al.  Species-Specific Metabolism of SGX523 by Aldehyde Oxidase and the Toxicological Implications , 2010, Drug Metabolism and Disposition.

[21]  R. J. Price,et al.  Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase , 2002, Xenobiotica; the fate of foreign compounds in biological systems.

[22]  T. Akabane,et al.  A practical and direct comparison of intrinsic metabolic clearance of several non-CYP enzyme substrates in freshly isolated and cryopreserved hepatocytes. , 2012, Drug metabolism and pharmacokinetics.

[23]  Deepak Dalvie,et al.  Aldehyde oxidase: an enzyme of emerging importance in drug discovery. , 2010, Journal of medicinal chemistry.

[24]  J B Houston,et al.  Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.

[25]  C. Beedham,et al.  Biotransformation of carbazeran in guinea pig: effect of hydralazine pretreatment. , 1994, Xenobiotica; the fate of foreign compounds in biological systems.

[26]  D. Greenblatt,et al.  Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo , 1998, Clinical pharmacology and therapeutics.

[27]  M. Rashidi,et al.  In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[28]  M. Fratelli,et al.  Avian and Canine Aldehyde Oxidases , 2006, Journal of Biological Chemistry.

[29]  T Ishizaki,et al.  Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2. , 1995, British journal of clinical pharmacology.

[30]  R. Obach.  Predicting clearance in humans from in vitro data. , 2011, Current topics in medicinal chemistry.

[31]  Daniel R. Albaugh,et al.  Characterization of Aldehyde Oxidase Enzyme Activity in Cryopreserved Human Hepatocytes , 2012, Drug Metabolism and Disposition.

[32]  Diao Xing-xin.  The role of aldehyde oxidase in drug metabolism , 2014 .

[33]  D. G. Walters,et al.  Inhibition of zaleplon metabolism by cimetidine in the human liver: in vitro studies with subcellular fractions and precision-cut liver slices , 2002, Xenobiotica; the fate of foreign compounds in biological systems.

[34]  Jeffrey P. Jones,et al.  The Impact of Single Nucleotide Polymorphisms on Human Aldehyde Oxidase , 2012, Drug Metabolism and Disposition.

[35]  C. Walsh,et al.  The behavior and significance of slow-binding enzyme inhibitors. , 2006, Advances in enzymology and related areas of molecular biology.